Last reviewed · How we verify
Allocetra - Randomization phase
At a glance
| Generic name | Allocetra - Randomization phase |
|---|---|
| Sponsor | Kaplan Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Intra-articular Allocetra in Knee Osteoarthritis (PHASE1, PHASE2)
- A Phase 2 Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients (PHASE2)
- Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint (PHASE1, PHASE2)
- A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allocetra - Randomization phase CI brief — competitive landscape report
- Allocetra - Randomization phase updates RSS · CI watch RSS
- Kaplan Medical Center portfolio CI